Pluses and minuses.
If they aim to have the study commencing 1H 2023, then that maybe means FDA has given its blessing to the general trial strategy. Hopefully, they can fund it on good terms.
Koo you raised a big one. Seems like a shot in the dark, to me. There is no clinical data to speak of for long covid.
Also, I think we're all wise to the fact that 1H 2023 doesn't actually mean 1H 2023.
1H 202__?
Something I've been wondering these past couple of years: Can the FDA rescind breakthrough status if the company is just squatting on it (as seems to be the case here)?
